Examining the Architecture of Next-Gen Biotherapeutic Modalities

Fri, Apr 17, 2026 11:00 AM EDT (8:30 PM Asia/Calcutta)

Event Overview:

This episode of BioPharm Drug Digest will examine the technical shift in development pipelines toward multifunctional biotherapeutic modalities. The episode will dive into innovations in the design of new modalities for antibodies, RNA therapy, and cell therapy, such as the use of programmable biology and next-generation delivery platforms. By leveraging accelerated regulatory pathways and precision-driven discovery, the biopharmaceutical industry is effectively reshaping the design, durability, and global scalability of the next generation of biotherapeutics.

Key Learning Objectives:

• Insight into designing multifunctional antibody therapies
• How new approaches like programmable biology impact precision
• Optimization of next-generation drug delivery systems
• How innovative approaches like digitized biology models can scale therapy development

Who Should Attend:

• R&D and biotherapeutic design scientists
• process development and manufacturing engineers
• regulatory affairs and clinical development specialists
• digital transformation and data scientists

Featured Speaker:

Dr. Abraham has more than 20 years of experience in cell and gene therapy and biomanufacturing. He leads global commercial strategy and innovation to help clients accelerate development and scale manufacturing. Previously, he held senior roles at National Resilience, Lonza, and Pluristem. Dr. Abraham earned his PhD from the University of Maryland and completed postdoctoral training at Harvard-MIT and Harvard Medical School.

For any technical questions please contact Brandon Clavijo: bclavijo@mjhlifesciences.com